HER2 Support Group Forums - View Single Post - Lani's Biospecimen Repository Proposal -- PLEASE READ

AlaskaAngel · 01-04-2008, 05:24 PM

Cynthia,

It is exciting to see yet another person with knowledge in this area working through the complications to make a HER2 registry a reality.

I am interested in knowing whether you or your research contacts consider the worldwide renowned researchers involved in the TEACH trial to be a collective group such as the one you propose would be involved in a registry for HER2 samples.

The TEACH clinical trial is made up solely of HER2 tumor samples and medical histories from patients around the world. Granted, it involves only those who have done chemotherapy and have never had Herceptin. However, as I understand it, all of these samples are from tumors collected prior to any treatment. They may be all the more valuable in that they were collected from trial participants who at start of trial are all NED even years out from treatment. Can we learn from this set of already collected worldwide HER2-only samples in any way, or not, in working toward our goal?

AlaskaAngel

01-04-2008, 05:24 PM	#3
AlaskaAngel Senior Member Join Date: Sep 2005 Location: Alaska Posts: 2,018	A preliminary question for Cynthia, Lani, or anyone Cynthia, It is exciting to see yet another person with knowledge in this area working through the complications to make a HER2 registry a reality. I am interested in knowing whether you or your research contacts consider the worldwide renowned researchers involved in the TEACH trial to be a collective group such as the one you propose would be involved in a registry for HER2 samples. The TEACH clinical trial is made up solely of HER2 tumor samples and medical histories from patients around the world. Granted, it involves only those who have done chemotherapy and have never had Herceptin. However, as I understand it, all of these samples are from tumors collected prior to any treatment. They may be all the more valuable in that they were collected from trial participants who at start of trial are all NED even years out from treatment. Can we learn from this set of already collected worldwide HER2-only samples in any way, or not, in working toward our goal? AlaskaAngel